Curis has started dosing patients in a Phase l trial of CA-4948 to treat patients with lymphoma.
CA-4948 is an orally available small molecule inhibitor of IRAK4 kinase, and the second licensed programme from a partnership between Curis and Aurigene to enter the clinic.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Phase l trial seeks to assess the safety, tolerability, and pharmacokinetic profile of CA-4948.
It also aims to identify any dose-limiting toxicities and establish the recommended Phase ll dose for treatment of patients with lymphomas.
The trial’s dose escalation stage will enrol patients with relapsed/refractory non-Hodgkin’s lymphoma, while the expansion stage will focus on specific populations of patients with lymphomas harbouring alterations in the MYD88 gene or toll-like receptor (TLR) signalling pathway.
Curis president and CEO Ali Fattaey said: “Given the prevalence of activating mutations in the MYD88 gene and the TLR pathway, IRAK4 represents a significant target for the precision treatment of patients with different hematologic malignancies.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“In addition to its preclinical anti-tumor activity in MYD88-mutated lymphomas, we have observed encouraging effects of CA-4948 in animal models of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) as well as non-oncology inflammatory disease models.”
In addition, Curis has partnered with Aurigene to collaborate in the fields of immuno-oncology and precision oncology.
